Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Velneperit

Stage Phase 2Stale

Sponsor Shionogi

Route oral

Sources

registry, as of 2018-05-01Stale

https://clinicaltrials.gov/study/NCT00788528

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 766. Conditions Obesity. The purpose of this open-label extension study is to evaluate the safety and efficacy of velneperit (S-2367) in obese subjects.

ClinicalTrials.gov NCT00788528 protocol and results modules

registry, as of 2018-05-11Stale

https://clinicaltrials.gov/study/NCT00748605

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 842. Conditions Obesity. 1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800 kcal deficit reduced calorie diet (RCD) compared with

ClinicalTrials.gov NCT00748605 protocol and results modules

registry, as of 2018-05-11Stale

https://clinicaltrials.gov/study/NCT00747929

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 724. Conditions Obesity. 1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects 2. To evaluate the safety and tolerability

ClinicalTrials.gov NCT00747929 protocol and results modules

Studies

OLE

Registry NCT00788528

Phase Phase 2

Status Completed

Enrollment 766

Arm A

Regimen once daily

Population Obesity

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Registry NCT00748605

Phase Phase 2

Status Completed

Enrollment 842

Placebo

Regimen once daily

Weeks 54

Population Obesity

S-2367 1600 mg q.d. 54 weeks

Dose 1600 mg

Regimen once daily

Weeks 54

Comparator placebo

Population Obesity

S-2367 1600 mg q.d. 60 weeks

Dose 1600 mg

Regimen once daily

Weeks 54

Comparator placebo

Population Obesity

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Registry NCT00747929

Phase Phase 2

Status Completed

Enrollment 724

S-2367 Placebo

Regimen once daily

Population Obesity

S-2367 800 mg

Dose 800 mg

Regimen once daily

Comparator placebo

Population Obesity

S-2367 1600 mg

Dose 1600 mg

Regimen once daily

Comparator placebo

Population Obesity